Federal Court Approves $70M Drug Price Inflation Settlements
Federal court approved two $70 million antitrust settlements over generic drug price inflation.
Why it matters: These settlements mark notable progress in combating illegal price-fixing in generic drugs, affecting corporate counsel and policymaking on pharmaceutical pricing.
- $29.6 million settlement with Glenmark Pharmaceuticals for price-fixing and market allocation.
- Settlement requires Glenmark to cooperate with ongoing litigation against 33 corporations and 25 executives.
- Consumers who purchased drugs from several manufacturers between 2009-2019 may be eligible for compensation.
- Pfizer and its unit Greenstone were dismissed from related price-fixing claims due to insufficient evidence.
On July 15, 2026, a coalition of 48 states and territories secured a $29.6 million settlement with Glenmark Pharmaceuticals to resolve allegations of conspiring to inflate prices and allocate markets in the generic drug sector. Glenmark's agreement includes cooperating with ongoing multistate litigation targeting 33 corporate defendants and 25 individual executives, as well as implementing internal antitrust compliance reforms. This settlement complements previous resolutions with firms like Lannett, Bausch, Apotex, and Heritage, which collectively contributed $66.95 million.
Consumers who purchased generic prescription drugs from these and related manufacturers between May 2009 and December 2019 may be eligible for compensation, as these illegal practices undermined the affordability of essential medications.
Meanwhile, federal Chief Judge Michael Shea dismissed Pfizer and its former unit Greenstone from similar price-fixing lawsuits, citing insufficient evidence of conspiracy during the years 2010 to 2014. This dismissal highlights the challenges in proving coordinated misconduct in such complex cases.
State attorneys general emphasize the importance of competitive pricing in healthcare. Colorado AG Phil Weiser noted, "Generic drugs are supposed to make health care more affordable through competition, not become the subject of illegal price-fixing schemes." Connecticut AG William Tong added that Glenmark "conspired with manufacturers across the generic drug industry to jack up prices and block competition." New York AG Letitia James stressed the impact on patients reliant on affordable generics for chronic illnesses.
These settlements and ongoing investigations underscore efforts to protect consumers and restore integrity to the generic drug market across the United States.
By the numbers:
- $29.6 million — Glenmark's settlement amount for drug price-fixing allegations
- 33 corporate defendants and 25 executives — parties involved in ongoing multistate litigation
- May 2009 to December 2019 — purchase period for potentially eligible consumers
Yes, but: Pfizer and its unit Greenstone were dismissed from related lawsuits due to lack of sufficient evidence, indicating some challenges remain in securing convictions across all defendants.
What's next: Ongoing litigation continues against the remaining 33 corporate defendants and 25 individual executives involved in the generic drug price-fixing cases.